SERNIVO Drug Patent Profile

When do Sernivo patents expire, and when can generic versions of Sernivo launch?

Sernivo is a drug marketed by Primus Pharms and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has seven patent family members in five countries.

The generic ingredient in SERNIVO is betamethasone dipropionate. There are sixty-six drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sernivo

A generic version of SERNIVO was approved as betamethasone dipropionate by FOUGERA PHARMS on June 26^th, 1984.

Summary for SERNIVO

International Patents:	7
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	50
Drug Prices:	Drug price information for SERNIVO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SERNIVO
What excipients (inactive ingredients) are in SERNIVO?	SERNIVO excipients list
DailyMed Link:	SERNIVO at DailyMed

See drug prices for SERNIVO

See drug sales revenues for SERNIVO

Pharmacology for SERNIVO

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Paragraph IV (Patent) Challenges for SERNIVO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SERNIVO	Topical Spray	betamethasone dipropionate	0.05%	208079	1	2018-02-15

US Patents and Regulatory Information for SERNIVO

SERNIVO is protected by seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Primus Pharms	SERNIVO	betamethasone dipropionate	SPRAY;TOPICAL	208079-001	Feb 5, 2016		RX	Yes	Yes			Y
Primus Pharms	SERNIVO	betamethasone dipropionate	SPRAY;TOPICAL	208079-001	Feb 5, 2016		RX	Yes	Yes			Y
Primus Pharms	SERNIVO	betamethasone dipropionate	SPRAY;TOPICAL	208079-001	Feb 5, 2016		RX	Yes	Yes			Y
Primus Pharms	SERNIVO	betamethasone dipropionate	SPRAY;TOPICAL	208079-001	Feb 5, 2016		RX	Yes	Yes			Y

International Patents for SERNIVO

See the table below for patents covering SERNIVO around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	2473161
European Patent Office	2473161	COMPOSITIONS TOPIQUES CONTENANT UN STÉROÏDE (TOPICAL FORMULATIONS COMPRISING A STEROID)
European Patent Office	3141246
Spain	2637447

SERNIVO (betamethasone dipropionate) Market Dynamics and Financial Trajectory (U.S.)

Last updated: July 21, 2026

SERNIVO (betamethasone dipropionate) is a topical corticosteroid marketed for inflammatory dermatoses responsive to corticosteroids. Public financial disclosures and commercialization specifics are not available at the level required for a quantified market size, revenue trajectory, or company-by-company profitability analysis in the U.S. under current constraints.

What is SERNIVO and how is it positioned in the topical corticosteroid market?

SERNIVO is a topical betamethasone dipropionate product in the high-potency class of topical corticosteroids, used for conditions where anti-inflammatory activity in the skin is needed. Competitive positioning for topical steroids typically hinges on:

• Strength classification (potency tier)
• Vehicle (cream/ointment/gel solution foam, etc.)
• Formulation differentiation (irritation profile, absorption, occlusion characteristics)
• Prescriber familiarity and payer contracting

Market structure for topical corticosteroids

• The class is crowded with generics and multiple branded options, with pricing pressure driven by interchangeability.
• High-potency topical steroid segments often see faster erosion after generic availability because therapeutic effect is largely category-driven rather than drug-specific.

Which therapeutic indications drive demand for SERNIVO?

Demand for high-potency topical corticosteroids is generally tied to:

• Psoriasis and related steroid-responsive dermatoses
• Eczema/dermatitis flares where high-potency agents are used
• Physician treatment patterns for body site and severity

What vehicle or strength details matter for competitive outcomes?

For topical corticosteroids, payer and prescriber decisions often depend on:

• Vehicle suitability for location and skin integrity
• Step therapy placement
• Prior authorization rules for higher-potency agents

How do payer and formulary dynamics affect SERNIVO uptake and pricing?

Topical corticosteroids are typically subject to:

• Formulary tiering (preferred vs non-preferred)
• Quantity limits for certain plan designs
• Prior authorization for high-potency products
• Step edits that steer use to lower-cost alternatives

What drives net price compression in topical steroids?

The key mechanisms are category competition and generic substitution:

• Branded products face contracting pressure as formularies prefer lower-cost therapeutics.
• Even when branded remains on formulary, rebates and patient cost-sharing adjustments can shift net price downward.

How do step edits and prior authorization reshape the revenue curve?

Revenue trajectories for topical brands commonly follow a pattern:

• Initial growth from formulary entry and prescriber adoption
• Mid-period decline or plateau when generics strengthen preferred positioning
• Continued net revenue pressure as additional competitors are added or policy restricts access

When do exclusivity and patent expiry risk impact SERNIVO’s commercial trajectory?

For commercial trajectory planning, the critical question is not just whether a product has exclusivity, but whether there are:

• Patent-protected formulations, methods of use, and/or devices
• Orange Book-listed exclusivities and patent terms that delay generic substitution
• Litigation events that extend effective launch windows

How does the U.S. regulatory status shape timeline risk for generics?

If SERNIVO is protected by Orange Book patents and/or exclusivity, then generic risk is delayed. If patents are weak or already expired, Paragraph IV challenges and “at-risk” launches become plausible accelerants.

What is the key generic entry risk in topical corticosteroids?

Generic entry risk is typically high because:

• The active ingredient is small-molecule and widely manufacturable
• Formulation changes can be sufficient to design around, depending on patent coverage
• Payers often allow substitution if bioequivalence and labeling requirements are met

What competitive pressures are most likely to affect SERNIVO market share?

How does SERNIVO compare with branded and generic betamethasone dipropionate products?

Market share dynamics for topical corticosteroids typically follow:

• Lowest cost and preferred formulary positioning win prescriptions
• Vehicle and user experience influence adherence and switching
• Brand-to-generic switches rise when copays and net prices diverge

Which competitive axes matter most in real-world prescribing?

• Payer placement and prior authorization burden
• Prescriber habits in dermatology and primary care
• Patient adherence, tolerance, and site-specific comfort

How strong is the patent estate for SERNIVO and what does it imply for revenue durability?

A defensible answer requires an Orange Book patent map with:

• Patent numbers
• Claims coverage (composition, formulation, method-of-use)
• Expiration dates
• Any terminal disclaimers
• Litigation history (if any)

Under the constraints of this run, a complete and accurate patent estate review cannot be produced at the required data density level.

What is SERNIVO’s FDA pathway status and how does it affect its commercial timeline?

SERNIVO’s FDA marketing status influences market access and competitive entry, but quantifying this impact requires:

• Product approval history and application type (e.g., NDA vs ANDA vs 505(b)(2))
• Exclusivity and patent listings
• Approval dates for specific dosage forms and strengths

That required dataset is not available here in a way that supports a complete response.

What financial trajectory should investors and planners expect for SERNIVO?

A quantified financial trajectory needs:

• Revenue history (annual and quarterly)
• Launch timing and growth phase metrics
• Payer contracting and net-to-gross trends
• Generic entry timing and realized price erosion

No authoritative revenue series is included in the information available under these constraints. As a result, the only actionable conclusion is that SERNIVO’s revenue durability in topical steroids is structurally sensitive to:

• Generic substitution risk
• Formulary access outcomes
• Step edit and prior authorization tightening

Key commercialization risk map for SERNIVO

Where revenue is most exposed

• High formulary sensitivity: preferred list positions and rebate-driven net pricing
• Switching risk: betamethasone dipropionate molecules with multiple suppliers
• Policy risk: plan redesigns that move high-potency topicals off preferred tiers

Where revenue is most defensible

• If there is strong patent coverage on formulation or use
• If a differentiated vehicle improves adherence enough to retain prescribing under formulary pressure
• If contracting keeps net price competitive versus generics

Key Takeaways

• SERNIVO is a high-potency topical corticosteroid in a highly competitive, pricing-sensitive segment with rapid generic substitution dynamics.
• Commercial outcomes in topical steroids are dominated by formulary access, step edits, prior authorization, and net price compression rather than long-term brand exclusivity in most cases.
• A quantitative financial trajectory and patent-expiry risk schedule cannot be produced here without an Orange Book and revenue dataset at the required level of precision.

---

FAQs

1) What factors most influence prescription demand for SERNIVO versus other topical corticosteroids?
Formulary placement, copays/net price, prior authorization requirements, and vehicle-based patient tolerability.

2) How does generic substitution typically change revenue for high-potency topical steroid brands?
Revenue usually compresses after generic availability and preferred formulary switching, often with continued use only where specific differentiation or coverage constraints remain.

3) What does Paragraph IV litigation change for topical corticosteroid brands?
It can accelerate generic entry or extend exclusivity indirectly through settlement and court timelines, depending on the dispute outcome.

4) How do vehicle and strength affect payer decisions for topical betamethasone products?
Vehicle and potency tier influence step edits, coverage thresholds, and the plan’s preferred list strategy for safety and cost.

5) What regulatory status elements matter most for forecasting SERNIVO competitive pressure?
Orange Book patent and exclusivity coverage, product approval history, and the timing of any patent expirations relevant to the exact dosage form and strength.

---

References (APA)

No sources were cited because no verifiable Orange Book, FDA approval, litigation, or revenue-history dataset was provided in the available information for this run.